New products mean solid revenue may be ahead for these companies.
News & Analysis: Amgen
Investors reacted positively to a big patent litigation win for the biotech.
Amgen's stock ripped higher in April. Here's why.
Amgen was one of the few blue chip stocks to post a gain during the month of March. Here's why.
Investors worried about a slowdown in revenue as biosimilars are rivals to older drugs.
Amgen's shares posted stellar gains last month. Can this blue chip biotech stock keep churning higher?
Amgen's best-selling medicine is safe from biosimilar competition for now.
The biotech's shares perked up for two unrelated reasons last month.
Shares jump after management lays out a road map for the year ahead.
The FDA and Trump administration indirectly added billions of dollars to Amgen's market value last month.
Shares swooned after the FDA announced that it needs more time to review the company's pending application.